The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Official Title: Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer
Study ID: NCT00654238
Brief Summary: The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Pennsylvania - Abramson Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
Name: Marcia S Brose, MD PhD
Affiliation: Unviersity of Pennsylvania - Abramson Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR